SUO 2020: Advanced Kidney Cancer Update – “A Glimpse into the Future”
(UroToday.com) In this state-of-the-art presentation, Dr. Toni Choueiri gave an overview of the management of advanced kidney cancer.
SUO 2020: Systemic Therapy for Metastatic Urothelial Carcinoma
(UroToday.com) At this year’s Society of Urologic Oncology (SUO) annual meeting Vadim S. Koshkin presented on systemic therapy for metastatic urothelial carcinoma. The current state of first-line metastatic urothelial carcinoma is shown in Figure 1.
SUO 2020: The Future of Prostate Cancer Screening
(UroToday.com) At this year’s Society of Urologic Oncology (SUO) annual meeting Dr. Klein was awarded the prestigious Richard D. Williams prostate cancer research excellence award. In this session, he gave a presentation on prostate cancer screening and cancer screening in general.
SUO 2020: Management of “Node Only” M1 Metastatic Bladder Cancer- Against Surgery
(UroToday.com) Dr. Arjun Balar presented on the management of “node only” metastatic bladder cancer, debating against the use of surgery following chemotherapy. He began his talk with some fundamental principles.
SUO 2020: Debate: Neoadjuvant vs. Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma – Adjuvant
(UroToday.com) In this debate, Dr. Tracy Rose presented why adjuvant chemotherapy should be used in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy. She began with a description of the POUT trial.1 This is a landmark trial, which was a phase 3, open-label prospective randomized-controlled trial conducted at 71 hospitals in the UK. This trial showed that […]
SUO 2020: Genomic Characterization of Residual Disease at Radical Cystectomy Following Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
(UroToday.com) During the Best of Bladder Cancer session during the 2020 Society of Urologic Oncology (SUO) annual meeting, Dr. Andrew Lenis presented on his group’s experience with genomic characterization of cystectomy patients. Currently, the standard of care for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy. The majority of studies in this space […]
SUO 2020: Factors Associated with Decision Regret in Patients Undergoing Radical Cystectomy and Urinary Diversion
(UroToday.com) Dr. Elizabeth Green was invited to speak during the last bladder cancer session of the 2020 Society of Urologic Oncology (SUO) annual meeting. Her group has investigated factors associated with decisional regret in patients undergoing radical cystectomy and urinary diversion.
[Urethral strictures: a variety of treatments requiring regular practice].
Urethral stricture is defined by a decrease in the caliber of the urethral lumen which can cause a decrease or an interruption of the urine flow. This disease is much more common in men than in women, and several causes can be identified.
Quality of life and sexual function after TVT surgery versus Bulkamid injection for primary stress urinary incontinence: 1 year results from a randomized clinical trial.
To assess changes in quality of life (QoL) and sexual function outcomes at 1 year after tension-free vaginal tape (TVT) versus polyacrylamide hydrogel injection (PAHG). In a randomized trial comparing TVT (n = 111) and PAHG (n = 113) treatments of stress urinary incontinence (SUI), we compared urinary incontinence and health-related QoL using the Urogenital Distress Inventory (UDI-6), Incontinence Impact […]
[Stress urinary incontinence in men].
Male stress urinary incontinence is predominantly iatrogenic, whereby radical prostatectomy is the most frequent cause. The first-line treatment of postoperative stress urinary incontinence is physiotherapy, in which training of pelvic floor muscles and sphincter play a major role.